CA2990835A1 - Compositions and methods for treating cancer - Google Patents

Compositions and methods for treating cancer Download PDF

Info

Publication number
CA2990835A1
CA2990835A1 CA2990835A CA2990835A CA2990835A1 CA 2990835 A1 CA2990835 A1 CA 2990835A1 CA 2990835 A CA2990835 A CA 2990835A CA 2990835 A CA2990835 A CA 2990835A CA 2990835 A1 CA2990835 A1 CA 2990835A1
Authority
CA
Canada
Prior art keywords
pp2a
inhibitor
kinase inhibitor
protein kinase
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2990835A
Other languages
English (en)
French (fr)
Inventor
Goutham Narla
Michael Ohlmeyer
Daniel McQuaid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Case Western Reserve University
Icahn School of Medicine at Mount Sinai
Original Assignee
Case Western Reserve University
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Case Western Reserve University, Icahn School of Medicine at Mount Sinai filed Critical Case Western Reserve University
Publication of CA2990835A1 publication Critical patent/CA2990835A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2990835A 2015-06-23 2016-06-23 Compositions and methods for treating cancer Abandoned CA2990835A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562183517P 2015-06-23 2015-06-23
US62/183,517 2015-06-23
PCT/US2016/039022 WO2016210134A1 (en) 2015-06-23 2016-06-23 Compositions and methods for treating cancer

Publications (1)

Publication Number Publication Date
CA2990835A1 true CA2990835A1 (en) 2016-12-29

Family

ID=57586472

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2990835A Abandoned CA2990835A1 (en) 2015-06-23 2016-06-23 Compositions and methods for treating cancer

Country Status (8)

Country Link
US (1) US10744141B2 (https=)
EP (1) EP3313819A1 (https=)
JP (1) JP2018518522A (https=)
CN (1) CN108779073A (https=)
AU (1) AU2016281646A1 (https=)
CA (1) CA2990835A1 (https=)
IL (1) IL256523A (https=)
WO (1) WO2016210134A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3352753A4 (en) 2015-09-24 2019-03-13 The Regents of The University of California SYNTHETIC SPHINGOLIPIDE-SIMILAR MOLECULES, MEDICAMENTS, METHODS FOR THEIR SYNTHESIS AND TREATMENT PROCEDURES
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
EP4121031A4 (en) * 2020-03-20 2024-03-27 Atux Iskay LLC 3-DIARYLMETHYLENE AND THEIR USE
KR20230017167A (ko) * 2020-04-01 2023-02-03 엔진 바이오사이언시즈 피티이. 엘티디. 암을 치료하기 위한 방법 및 조성물
WO2022094615A1 (en) * 2020-10-29 2022-05-05 The Regents Of The University Of California Compounds and methods for increased antisense activity
CN114617969B (zh) * 2020-12-14 2023-08-25 上海市肿瘤研究所 乐伐替尼和Aurora-A激酶抑制剂在制备抑制癌症的药物中的应用
CN116806217A (zh) * 2021-02-08 2023-09-26 拉帕塔疗法公司 蛋白磷酸酶2a(pp2a)的取代的环状调节剂及其使用方法
AU2022216880A1 (en) * 2021-02-08 2023-08-10 Rappta Therapeutics Oy Substituted cyclic modulators of protein phosphatase 2a (pp2a) and methods using same
CN112816453B (zh) * 2021-02-09 2022-07-08 黑龙江大学 蛋白在预测药物性能上的应用
US20240368105A1 (en) 2021-08-18 2024-11-07 Atux Iskay Llc 2-diarylmethyl-4-aminotetrahydropyran derivatives and related compounds as anticancer, antiinflammatory, antifibrotic and neuroprotective agents
CN113616795B (zh) * 2021-08-31 2023-06-20 上海交通大学医学院附属瑞金医院 Pp2a激动剂防治由正常衰老或pp2a活性或表达降低所导致的精神障碍
CN114984221A (zh) * 2022-05-25 2022-09-02 浙江大学 Pp2a及其激活剂在急性缺血性脑卒中制药、标记的应用
CN116421726A (zh) * 2023-04-14 2023-07-14 中国海洋大学 一种基于分子预测的靶向plk1纳米药物的开发方法
WO2025230951A1 (en) * 2024-04-29 2025-11-06 Icahn School Of Medicine At Mount Sinai Method of treating adenoid cystic carcinoma

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045515A1 (en) * 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
EP1996193A2 (en) * 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
US20090020197A1 (en) * 2007-07-16 2009-01-22 Key Safety Systems, Inc. Gas generating compositions and airbag inflators
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
WO2009117769A1 (en) 2008-03-25 2009-10-01 Newcastle Innovation Limited Inhibition of c-kit cancers
JP2012523458A (ja) * 2009-04-13 2012-10-04 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション タンパク質ホスファターゼ２ａ活性化剤
US9134297B2 (en) * 2011-01-11 2015-09-15 Icahn School Of Medicine At Mount Sinai Method and compositions for treating cancer and related methods
HK1198384A1 (en) * 2011-08-16 2015-04-17 Mt. Sinai School Of Medicine Tricyclic compounds as anticancer agents
WO2013096687A1 (en) * 2011-12-22 2013-06-27 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer
WO2014151955A1 (en) * 2013-03-15 2014-09-25 Life Technologies Corporation Prognostic assay for squamous cell lung carcinoma
WO2015138500A1 (en) 2014-03-11 2015-09-17 Icahn School Of Medicine At Mount Sinai Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents
WO2015138496A1 (en) 2014-03-11 2015-09-17 Icahn School Of Medicine At Mount Sinai Constrained tricyclic sulfonamides

Also Published As

Publication number Publication date
WO2016210134A1 (en) 2016-12-29
IL256523A (en) 2018-02-28
EP3313819A1 (en) 2018-05-02
JP2018518522A (ja) 2018-07-12
AU2016281646A1 (en) 2018-02-01
US10744141B2 (en) 2020-08-18
US20180185382A1 (en) 2018-07-05
CN108779073A (zh) 2018-11-09

Similar Documents

Publication Publication Date Title
US10744141B2 (en) Compositions and methods for treating cancer
JP2022058398A (ja) Ｂｒａｆ－ｖ６００関連疾患の治療に使用するためのｐｌｘ－８３９４またはｐｌｘ－７９０４
TWI784255B (zh) 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
Chen et al. Serotonin signalling in cancer: Emerging mechanisms and therapeutic opportunities
US11826363B2 (en) Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
JP5827962B2 (ja) Ｃｄｃ７キナーゼ阻害剤およびその使用
JP2022088616A (ja) 再発性神経膠腫および進行性の二次性脳腫瘍からなる群から選択される悪性腫瘍の治療に使用するための薬剤の調製方法
JP2022009090A (ja) 癌を治療するためのｋｒａｓ阻害剤の投与
JP2024037891A (ja) 黒色腫の治療のための組合せ医薬
JP2021501142A (ja) キナーゼを調節する化合物の製剤
UA119537C2 (uk) ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ
CN103596951A (zh) 用于治疗神经系统障碍和癌症的8-乙基-6-(芳基)吡啶并[2,3-d]嘧啶-7(8h)-酮
CN110831926B (zh) 新型四氢萘基脲衍生物
KR20180072704A (ko) 세스트린-gator2 상호작용의 조절제 및 이의 용도
JP2015512425A (ja) チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
JP2024533975A (ja) Ｐｉ３ｋアイソフォームアルファを阻害する化合物及びがんを処置するための方法
KR20140022053A (ko) Akt 및 mek 억제제 화합물의 조합물, 및 사용 방법
JP2018510134A (ja) 組合せがん治療法
JP6526789B2 (ja) 組み合わせ療法
JP2024542248A (ja) Ｆｇｆｒ阻害剤とｋｒａｓ阻害剤を含む併用療法
KR20200026925A (ko) 스타틴 조성물 및 시누클레인병변 치료에 사용하는 방법
US20190117663A1 (en) Compositions and methods for treating cancer
KR20140145604A (ko) 암 치료용 키나제 저해제
WO2019018785A2 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM TUMORS
Sola et al. Melatonin and Cancer: New Insights

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20200831